MAPT and Alzheimer disease: In conclusion, we described here for the first time the generation of novel vaccine candidates against AD based on MVA vectors expressing either the full-length human Tau 4R2N isoform (MVA-Tau4R2N) or the human tau 3RC mutant protein (MVA-Tau3RC).